What makes 
SPRAVATO® different?

Actor portrayal.

The first and only NMDA receptor antagonist approved for 2 subtypes of MDD in adult patients1

SPRAVATO® hypothesized mechanism of action (MOA)



Estimated to have MDD

17.6 million adults are estimated to have MDD in the US.5

active suicidal ideation

11.5% of these patients have active suicidal ideation with intent.5

administered oral antidepressant

These patients need timely attention, but a newly administered oral antidepressant may take 4 to 6 weeks to reach full effect.6

SPRAVATO® clinical program overview

Studied in 449 adult patients with moderate to severe MDD who had active suicidal ideation with intent, across all studies



Patients included in MDSI trials had active suicidal ideation or behavior that was characterized by the following:

 Thinking (even momentarily) about harming or hurting or injuring oneself

 Having awareness that they might die as a result of self-harm

 Intend to act on thoughts of killing oneself


Patients had a mean MADRS score of 40


Patients reported active, acute suicidal ideation within 24 hours prior to their first dose of study medication

MADRS=Montgomery-Åsberg Depression Rating Scale.

Patients in both arms received comprehensive standard-of-care (SOC) treatment, including an initial inpatient psychiatric hospitalization and a newly initiated or optimized oral antidepressant (AD) therapy (AD monotherapy or AD plus augmentation) as determined by the investigator


Next: Efficacy in TRD and MDSI

Learn more


1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.

2. Uher R, et al. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014;31:459-471.

3. Grunebaum MF, et al. Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology. 2012;37:697-706.

4. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer and Adherence. 2012;6:369-388.

5. Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.

6. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2010:1-152.